TEV-749 olanzapine LAI achieved 80% clinical stabilization in schizophrenia patients during the SOLARIS Phase 3 trial, with ...
Velocity Clinical Research appoints Justin Starzyk as CEO to lead its 70+ research sites across the U.S. and Europe.
CHMP recommends Ocrevus pediatric relapsing MS approval for children aged 10+, advancing toward European Commission ...
FDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancer, doubling progression-free survival in Phase 3 ...
New analysis suggests nonmelanoma skin cancer cases are 42% higher than official counts, with annual patient numbers reaching ...
Kamada confirms KedRAB supply meets surge in rabies inquiries. CDC reports 17% increase in rabies-related cases through ...
Certara launches External Data Accelerator to catch vendor data conformance issues before submission, addressing 70% of ...
PEDMARK hearing protection met its primary endpoint in a Phase 2 study, showing significant ototoxicity reduction without ...
Med-Gemini scores 91% on MedQA. OpenAI's o1-preview hits 96%. Neither number tells you what happens when the algorithm meets ...
Roche's Lunsumio combo met its primary endpoint in Phase III follicular lymphoma trial, beating rituximab plus lenalidomide ...
Boehringer Ingelheim's PED Essentials teaches patient organizations to collect and structure patient experience data for ...
MIRA Pharmaceuticals initiates Phase 2a study of Ketamir-2 for chemotherapy-induced peripheral neuropathy, targeting an undertreated condition affecting over ha ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results